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The direct estimate of 46,000 snakebite deaths in India in 2005 (1 for every 2 HIV/AIDS deaths), based on 
verbal autopsies, renders unrealistic the total of only 47,000 snakebite deaths in the whole world in 2010, 
obtained indirectly as part of the “Global Burden of Disease 2010” study. Persistent underestimation 
of its true morbidity and mortality has made snakebite the most neglected of all the WHO’s “neglected 
tropical diseases”, downgrading its public health importance. Strategies to address this neglect should 
include the improvement of antivenom, the only specific antidote to envenoming. To accommodate 
increased understanding of geographical intraspecific variation in venom composition and the range of 
snake species that are medically important in India, the design of antivenoms (choice of venom sources 
and species coverage) should be reconsidered. Methods of preclinical and clinical testing should be 
improved. The relatively new science of venomics involves techniques and strategies for assessing the 
toxin composition of snake venoms directly through proteomics-centred approaches or indirectly via 
high-throughput venom gland transcriptomics and bioinformatic analysis. Antivenomics is translational 
venomics: a proteomics-based protocol to quantify the extent of cross-reactivity of antivenoms against 
homologous and heterologous venoms. These approaches could revolutionize the preclinical assessment 
of antivenom efficacy, leading to a new generation of antivenoms that are clinically more effective.
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 When most people involved in public health think of 
neglected tropical diseases (NTDs) that affect the lives 
of men, women and children throughout the developing 
economies of the world, their minds usually turn to a 
conflagration of tropical infectious diseases including 
guinea worm, leishmaniasis, dengue, onchocerciasis, 
Chagas disease, leprosy and lymphatic filariasis. The 
World Health Organization (WHO) agrees. Supported 
by drug makers and special interest groups, WHO 
initiated a coordinated effort to address a number 
of these diseases in 2005. That effort has steadily 
mushroomed, resulting in publication of a landmark 
report on these problems in 2010, that gave rise to 
a strategic plan for eradication and control efforts1. 
Today WHO lists 17 NTDs on its website as targets 
for eradication. At the WHO’s World Health Assembly 
on 27th May 2013, resolution EB132.R7 was adopted, 
urging member States to expand their programmes 
to prevent, control, eliminate and eradicate all 17 of 
these NTDs2. But what few people will know is that 
in March 2009, WHO added snakebite to its official 
list of NTDs, and then quietly demoted it, along with 
podoconiosis and strongyloidiasis to a separate listing 
of what it calls “other neglected conditions”; a list that 
is included in none of WHO’s plans to eradicate NTDs, 
or even mentioned in either its 2010 report, or the 
recently available 2013 report1,3. Such a move seems 
to be the way in which the public health community 
considers snakebite, begrudgingly admitting to it, 
but then quietly relegating it to the category of being 
too difficult to achieve, despite the reality that this 
forgotten tropical disease continues to impose a 
tremendous cost of suffering and chronic disability on 
many of the world’s poorest and most disenfranchised 
communities4.
 Persuading the global community to take serious 
notice of the extent to which families and even whole 
communities are fractured by snakebites is a challenge 
that is being taken up by scientists, doctors and others 
who have been confronted by the tragedy of lives lost or 
bodies crippled by what is essentially a preventable and 
treatable illness. In 2008, members of the international 
toxinology community established the Global Snakebite 
Initiative (GSI), since when its members have worked 
towards developing an integrated new approach to 
improving therapeutic management of snakebite, 
and addressing issues ranging from prevention, to 
health-worker training and victim rehabilitation5-7. 
At the core of the GSI strategy is the desire to couple 
modern proteomic, immunological, pharmacological 
and molecular biological techniques to the quest for 
improved therapeutics and the understanding of the 
underlying pathophysiology and biomechanics of 
snakebite injuries7-10. Among the links being forged by 
the GSI, are partnerships with Indian researchers and 
institutions interested in the challenge of improving both 
the treatment of snakebite in India, and the outcomes 
for the million or more people bitten each year.
 India has had a long and tumultuous relationship 
with serpents, which are both revered and feared. Some 
of the earliest reports of snakebite from India during 
British colonial rule spoke of fatalities in the tens of 
thousands. Sir Joseph Fayrer who championed the 
destruction of India’s snakes as the best means to curb 
human deaths, wrote in a report to Nature published 
on December 28, 1882, that snakebite had caused the 
deaths of 11,416 people across seven administrative 
regions representing about half of what was then 
British India (including modern Burma and Pakistan) 
in 1869, but he believed this to be an under-estimate 
of the true burden11. Fayrer believed between 150,000 
and 200,000 deaths due to snakebite had occurred in 
India from 1870-1882, citing 19,060 human deaths in 
1880 and 18,610 in 1881. During this two year period 
the government paid out 23,623 rupees in bounties for 
467,744 snakes killed under eradication programmes 
that Fayrer had fought to have instituted. Numerically, 
the highest numbers of fatalities in 1880/81 were 
recorded in the heavily populated Bengal (19,272), and 
the North-West Provinces/Aoudh (9,733), which also 
had the highest mortality rates relative to population size 
(15.93/100,000/yr and 11.04/100,000/yr, respectively) 
along with the Central Provinces (11.50/100,000/
yr) and the small population of Ajmere-Marwara 
(10.30/100,000/yr)12. Using population data from the 
time provided in a letter to the British Medical Journal 
by Dr Edward Nicholson in 188312, the mortality rate 
for snakebite right across British India for 1880/81 
averaged 10 deaths per 100,000/yr, a figure which if 
true today would equate to more than 163,504 deaths/
yr across the former British India (excluding Sri 
Lanka) of which more than 122,000 would occur in 
present day India. Fayrer’s claim of up to 200,000 
deaths from 1870-1882 is supported by what were 
said to be incomplete annual figures from the British 
Administration in India13. It reported that 21,391 deaths 
occurred in 1875, 19,279 in 1876 and 22,125 in 1882. 
The 1876 figure is cited as the lowest number between 
1875-1882. Thirty years of reports published in 1913 
continued to put the annual death toll from snakebite 
at more than 20,000 per year14. In 1909, there were 
21,634 deaths across the British colonies, and 22,478 
were recording in 1910, with 7,767 of these occurring 
in Bengal14. Bombay (now Mumbai) saw far fewer 
snakebites than Bengal. In 1902 and 1903 there were 
1,288 and 1,074 deaths from snakebites, respectively 
representing 16.7 per cent of all the deaths from injury 
in that 2 year period15. In 1910, snakebites caused 
1,247 deaths in Bombay11. In 1924, there were 19,867 
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deaths from snakebites reported across British India, 
accounting for 2.35 per cent of all deaths recorded 
in the Public Health Commissioners annual report to 
government16.
 This review presents a modern summary 
of snakebite in India, and discusses how real 
improvements in the quality of snake antivenoms as 
front-line therapeutics can be achieved by embracing 
the opportunities presented by modern scientific 
technologies when applied to this age-old problem.
The global burden of snakebites
 The recently published Global Burden of Disease 
2010 estimated, from a large number of different 
sources, that the global total of deaths from animal 
contact (venomous) decreased from 54,900 (95% 
uncertainty intervals 30,100-89,300) in 1990 to 47,000 
(25,600-84,700) in 2010 and that deaths from “other 
neglected tropical diseases”, which include snakebites 
(http://www.who.int/neglected_diseases/diseases/en/)17, 
increased from 22,900 (14,300-29,500) in 1990 to 
23,700 (16,600 - 30,900) in 201018. The absurd 
inadequacy of these estimates is immediately apparent 
if one considers the direct estimate of 46,000 (99% 
confidence interval 41,000 - 51,000) snakebite deaths 
in India in 200519. Over the last half century, there have 
been a few attempts to discover the incidence of 
snakebite and its associated morbidity and mortality 
worldwide. In 1954, Swaroop and Grabb, using national 
hospital returns, suggested half a million bites with 
30,000-40,000 deaths each year but they had no data 
from China, USSR, or Central Europe20. In 1998, 
Chippaux used results of household surveys, together 
with hospital and health authority data to increase these 
figures almost five-fold to 5 million bites, 125,000 
deaths and 100,000 severe sequelae each year21. 
Evaluation of overall disease burden using the concept 
of disability adjusted life years (DALYs) produced the 
high estimate of 2 million DALYs per year for sub-
Saharan Africa17. In the most recent WHO-sponsored 
effort, Kasturiratne et al22 dredged the so-called “grey 
literature”, combining these suspect sources with 
hospital returns and by extrapolation between adjacent 
(and some not-so-adjacent) countries produced a figure 
of 420,549–1,841,158 envenomings (bites in which 
venom was injected) and 19,886 - 93,945 deaths each 
year. Assuming that envenoming occurred in about one 
in every four snakebites, they estimated that between 
1.2 and 5.5 million snakebites might occur annually. In 
all likelihood the only way in which the true burden 
will ever be known is if snakebites are made a reportable 
event by governments willing to invest in properly 
defining the impact of snakebite on public health and 
community well-being.
Snakebite incidence and mortality in India
 With the growth of human populations in South 
Asia since Sir Joseph Fayrer and others produced their 
first calculations of snakebite impact more than 130 years 
ago, one might expect that snakebite figures in India 
would have climbed with the burgeoning of humanity. 
Community-based surveys in Burdwan district, West 
Bengal23, and a neighbouring area just across the 
border in Nepal’s eastern Terai24, found surprisingly 
high annual incidences of snakebite deaths, 16.4 and 
162 per 100,000 population per annum, respectively. 
However, between 2004 and 2009, hospitals in 31 of 
the 35 States and Union Territories in India reported 
an average of only 1,350 snakebite deaths each year 
to the Government of India (http://cbhidghs.nic.in/
index2.asp?slid=985&sublinkid=694). These national 
totals were lower than older figures from single States. 
For example, in 1971, 1,476 snakebite deaths were 
recorded in Bombay Province, Maharashtra State and 
Ratnagiri district25. Controversy about the true burden 
of snakebite mortality in India should at last have 
been resolved by results of the Registrar General of 
India’s “Million Death Study” (MDS)19. All causes of 
all deaths were ascertained in 6,671 randomly chosen 
sample areas, each including about 1000 people. 
Verbal autopsy was used to identify snakebite deaths. 
This involves a structured interview of the relatives 
or close associates of the deceased conducted by non-
medical staff with central medical coding by at least 
two doctors. Verbal autopsy is reliable for snakebite 
because the fatal event is distinctive, dramatic and 
therefore memorable. However, some deaths may have 
been missed since some victims of nocturnal krait bites 
do not realize that they have been bitten and present 
with mysterious ‘early morning paralysis’ or seizures 
that would not be associated with snakebite26. In 2005, 
an estimated 46,000 people (99% CI 41,000 - 51,000) 
died of snakebite in India, approximately one for every 
two HIV/AIDS deaths19. Assuming that there are 100 
non-fatal bites for each fatal bite (from results of a 
community-based study in Bangladesh)27 there could 
be as many as 4.6 million snakebites in India each 
year. The MDS results indicate which States of India 
are worst affected: the highest numbers of deaths were 
in Uttar Pradesh (8,700), Andhra Pradesh (5,200), and 
Bihar (4,500), while Andhra Pradesh had the highest 
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incidence of mortality due to snakebite (6.2/100 000 
population/year)19. Snakebite accounts for 3 per cent 
of all deaths in children of the age of 5-14 yr. Ninety 
seven per cent of the victims of snakebite die in rural 
areas, 77 per cent of them outside health facilities, 
because they preferred traditional therapy from tantriks, 
vaidyas and ojhas. These figures should encourage the 
Ministry of Health to reassess the public health priority 
of snakebite and deploy its resources where these are 
most needed.
Approaches to preventing snakebites
 Snakebite in India is an occupational and 
environmental disease mainly affecting rural 
agricultural workers and their families. Prevention 
is all important. Like any form of health promotion, 
community education by all available means and 
media is crucial. The aim is to alert communities to the 
types of environments most frequented by dangerous 
species, and to advise them how to avoid being bitten. 
For example, cobras are most commonly found near 
water or in irrigated paddy fields, while Russell’s vipers 
frequent these areas especially at times of harvest when 
rodents are most abundant. The most dangerous time 
of year is usually during the monsoon and hot weather. 
Many bites are inflicted as people walk home or collect 
firewood in the dark after dusk or before dawn. Safer 
walking and safer working can be achieved by wearing 
protective shoes, boots or gloves and by carrying a 
light after dark. The risk of nocturnal krait bites can be 
mitigated by sleeping in a hammock, on a raised bed 
or under a well-tucked-in mosquito net28. Communities 
should be persuaded to abandon their preference for 
traditional treatments and, instead, to transfer bite 
victims to dispensaries, clinics or hospitals as quickly 
as possible. Steps must be taken to improve the medical 
treatment of snakebite (including the effectiveness 
and safety of antivenoms) to generate confidence in 
conventional medicine. Where there are no roads and 
limited means of transport, village-based motorcycle 
volunteers have proved effective for transporting 
obstetrical emergencies in Sierre Leone and patients 
with neurotoxic snakebites in the eastern Terai of Nepal 
“SK Sharma, personal communication”29. Once the 
patient has arrived in hospital, prevention of morbidity 
and mortality will depend on the training of medical 
staff and provision of necessary equipment, antivenom 
and other drugs. Guidelines for the SEARO region, 
including India, have been published by WHO30.
Indian snakes of medical relevance and the design 
of Indian polyvalent antivenoms
 India and its surrounding seas are inhabited by more 
than 60 species of venomous snakes some of which are 
sufficiently common to cause frequent bites and whose 
venoms are capable of severe envenoming31. Four 
species, common krait (Bungarus caeruleus) (Fig. 1a), 
spectacled cobra (Naja naja) (Fig. 2a), Russell’s viper 
(Daboia russelii) (Fig. 3a), and saw-scaled viper (Echis 
carinatus) (Fig. 4a) are distributed throughout virtually 
the whole country and have long been recognized 
as the most important causes of bites, deaths and 
Fig. 1. Envenoming by common krait (Bungarus caeruleus): (a) the snake (specimen from Pune, Maharashtra); (b) bilateral ptosis, external 
ophthalmoplegia and facial paralysis; (c) fang and tooth puncture marks without local swelling in the same patient as 1b.
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Fig. 2. Envenoming by common cobra (Naja naja): (a) the snake (specimen from Pune, Maharashtra); (b) local swelling, blistering and 
demarcated areas of dermonecrosis in a patient.
Fig. 3. Envenoming by Russell’s viper (Daboia russelii): (a) the snake (specimen from Pune, Maharashtra); (b) local swelling and blistering 
(Kerala); (c) chemosis, a sign of generalized increase in capillary permeability; (d) bilateral ptosis, external ophthalmoplegia and facial 
paralysis; (e) chronic pan-hypopituitarism (loss of secondary sexual hair and gynaecomastia) following a bite 3 years previously (Kerala).
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disability. Over the past century, venoms of only these 
four species have been used by Indian manufacturers 
to raise polyvalent antivenoms (also called anti-snake 
venoms, ASV, or anti-snakebite serums) for national 
use. However, there have been increasing concerns 
about the design of these antivenoms, due in part to 
recognition that many more species of venomous snakes 
are implicated in envenoming across India and also to 
ongoing concerns about the safety and effectiveness of 
products that have gained a reputation for being poorly 
manufactured in some cases, and poorly effective in 
published clinical studies of snakebites32.
Which species are responsible for snakebite 
envenoming in India?
 Apart from the widely distributed “big four”, there 
are a number of other species occurring in localized 
areas of the country that are now known to be capable 
of causing severe envenoming32:
 Monocellate cobra (N. kaouthia) - occurs in north-
eastern India, in many parts of which it causes more 
bites than N. naja with equally severe consequences. 
 Central Asian or Oxus cobra (N. oxiana) - is 
confined to the far north (Kashmir and Himachal 
Pradesh) where it is rare. No bites have been reported 
in India but it has proved dangerous in other parts of its 
range. 
 Kraits (Bungarus) - taxonomic revisions have 
elevated two former sub-species to the status of full 
species. Wall’s krait (Bungarus walli) occurs in the 
north-east and the Sind krait (B. sindanus) in the 
west. Bungarus sindanus has caused life-threatening 
envenoming in Maharashtra33 and Rajastan (Dr PD 
Tanwar, personal communication, February 2011). 
Bungarus walli has caused fatalities in Nepal and 
Bangladesh (unpublished data of Aniruddha Ghose, 
Md A. Faiz, Sharma SK, Harris JB, Kuch U, Warrell 
DA in preparation). The greater black krait (B. niger) 
occurs in the far north-east of India. In Bangladesh, 
it has caused fatal envenoming through generalized 
rhabdomyolysis and acute kidney injury (AKI), as well 
as by more familiar paralytic effects34. 
 King cobra (Ophiophagus hannah) - occurs in 
the Western Ghats and north-east India. It is the largest 
and potentially the most dangerous of all venomous 
snakes but is rare and elusive, causing very few bites 
and deaths35. 
 Levantine or snub-nosed viper (Macrovipera 
lebetina) - this large and dangerous species is confined 
to Jammu and Kashmir at altitudes above 900 m and 
has caused only one recorded bite in India35. 
 Pit-vipers (Crotalinae) - among the 15 Indian 
species, the hump-nosed pit-viper (Hypnale hypnale) 
(Fig. 5a) of the south-west coast and Western Ghats, 
where it has been misidentified as E. carinatus, has 
caused local necrosis, coagulopathy, bleeding and AKI37. 
The Himalayan pit-viper (Gloydius himalayanus) of the 
western Himalayas, bamboo pit-viper (Trimeresurus 
gramineus) of the Western and Eastern Ghats, large-
scaled pit-viper (Peltopelor macrolepis) of the south-
west37, mountain pit-viper (Ovophis monticola) of north 
and north-east and northern white-lipped green pit-viper 
(Cryptelytrops septentrionalis), red-tailed pit-viper (C. 
erythrurus) and some other arboreal green pit-vipers of 
the north-east, can cause local swelling, coagulopathy, 
bruising and bleeding. Envenoming by the Malabar pit-
viper (Trimeresurus malabaricus) of the Western Ghats38 
can cause local necrosis. The venoms of none of these 
species are covered by Indian polyvalent antivenoms.
 Sea-snakes (Hydrophiinae, Laticaudinae) - 
there have been a few reported cases of sea snake bites 
around the coast of India39 (Fig. 6).
Fig. 4. Envenoming by northern saw-scaled viper (Echis carinatus 
sochureki): (a) the snake (specimen from Bikaner, Rajasthan; (b) 
Bleeding from the gums (Bikaner) (courtesy of Dr PD Tanwar).
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always inflicted on people sleeping indoors on the 
ground. Local envenoming is absent or minimal (Fig. 
1c) and there is usually no local pain. However, severe 
crescendo abdominal pain may be a presenting symptom. 
Destructive, irreversible neurotoxicity that does not 
respond to antivenom is a feature of krait envenoming. 
Cobra bite envenoming causes, in addition, local 
envenoming: pain, swelling, regional lymphadenopathy, 
blistering and necrosis (Fig. 2b). Russell’s viper bite 
envenoming causes marked local envenoming (Fig. 
3b) and a variety of systemic manifestations: shock, 
coagulopathy, bleeding and AKI. In some parts of the 
country such as Kerala, there is generally increased 
capillary permeability (Fig. 3c). In others, such as 
Tamil Nadu, there is neuro-myotoxicity (Fig. 3d). 
The risk of anterior pituitary infarction resulting in 
fatal acute pituitary adrenal failure or chronic pan-
hypopituitarism occurs in southern India. Saw-scaled 
viper bites are usually less severe, lacking the risk of 
AKI, permeability and pituitary infarction but associated 
with local necrosis, coagulopathy and bleeding (Fig. 
4b). Hump-nosed viper bites are associated with 
local envenoming (Fig. 5b), coagulopathy, bleeding, 
microangiopathic haemolysis and AKI. Bites by other 
Indian pit-vipers can cause local envenoming resulting 
in necrosis, coagulopathy, bleeding rarely if ever in 
AKI. Generalised rhabdomyolysis causing myalgia 
followed by myoglobinuria and AKI is a feature of sea 
snakebite envenoming.
Fig. 5. Envenoming by hump-nosed viper (Hypnale hypnale): (a) the snake (specimen from Thattekkad, Kerala); (b) marked local swelling 
after a bite on the foot (Angamaly, Kerala).
Fig. 6. Beaked sea snake (Enhydrina schistosa): the snake (courtesy 
of Mark O’Shea). 
Clinical phenotypes of envenoming by Indian 
snakes
 Elapid envenoming is characterized by 
neurotoxicity, first evident as ptosis and external 
ophthalmoplegia (Fig. 1b) then involving muscles 
innervated by the cranial nerves in a descending pattern 
followed by the axial muscles of the trunk, resulting 
in respiratory paralysis and finally, if respiration is 
supported, generalized flaccid paralysis, partially 
sparing only the extremities. Krait bites are almost 
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Is Indian polyvalent antivenom equally effective in 
treating bites by the “big four” species throughout 
the whole of India?
 The phenomenon of intra-species variation in 
venom composition has been well documented in the 
cases of many species of viperid and elapid snakes40,41. 
Geographical diversity in venom antigenicity is the 
most important consideration in antivenom design. In 
India, there is evidence of such variation in the venoms 
of N. naja and D. russelii42,43 and yet 80 per cent of 
the venom currently used to raise Indian polyvalent 
antivenoms is collected by the Irula cooperative from 
snakes inhabiting one small area around Mahabalipuram 
in Tamil Nadu (http://www.madrascrocodilebank.org/
cms/conservation-and-research-2/the-irulas/). There is 
growing clinical suspicion that Indian antivenom may 
be less effective in some areas distant from the source 
of immunizing venoms. In Rajasthan, envenoming by 
the larger northern sub-species of the saw-scaled viper 
(Echis carinatus sochureki) requires larger doses of 
antivenom than for the smaller southern sub-species 
(E. c. carinatus)44. In Maharashtra and northern Kerala, 
antivenom appears to be less effective in the treatment 
of D. russelii envenoming. For example, in Kozhikode, 
treatment with generally accepted initial doses of 10-
20 vials of polyvalent antivenom within a few hours of 
the bite failed to prevent development of the syndrome 
of generalized increase in capillary permeability 
(capillary leak syndrome) (Dr Remi Thomas - personal 
communication, February 2012). 
Should the classic Indian polyvalent antivenoms be 
redesigned to provide broader cover?
 Because of geographical intra-species variation 
in venom composition and hence immunogenicity, 
the current practice of using venom from restricted 
geographical source(s) may have the result that 
envenoming even by the traditional ‘big four’ species 
may not be adequately treated by Indian polyvalent 
antivenoms. Ideally, venom pools including samples 
from a wide geographical range should be used for 
immunization. The range of species against which 
polyvalent antivenom is effective should also be 
expanded to cover some of the additional species. 
In a recent study, two Indian polyvalent antivenoms 
manufactured by Vins Bioproducts and Bharat Serums 
and Vaccines showed different levels of neutralization 
for both Indian and south-east Asian Naja and Bungarus 
venoms, indicating that polyvalent antivenoms produced 
in India, using the same source of venom, should not be 
assumed to be identical in their therapeutic potential45. 
In reconsidering their future strategy for antivenom 
design, the Indian authorities might decide to continue 
with one polyvalent antivenom with expanded range to 
cover the whole country or perhaps three new regional 
antivenoms. For example, NE (North-East) antivenom 
might include, in addition to the big four, N. kaouthia, 
B. walli, B. niger and one of the pit-vipers among its 
immunizing venoms; NW (North-West) - N. oxiana, B. 
sindanus, E. c. sochureki and M. lebetina; SW (South-
West)- B. sindanus, H. hypnale, T. malabaricus and T. 
gramineus.
Toolbox for the preclinical assessment of antivenom 
efficacy
 An ideal therapeutic antivenom should contain 
antibodies that can neutralize the widest possible 
range of medically important toxins to give the widest 
polyspecific coverage, using as few specific venoms as 
possible in its production. The large variation in the 
composition of snake venoms, both at the inter- and 
intra- species levels, has implications for the design 
of venom mixtures for immunization of animals 
for antivenom production and in the analysis of 
antivenom neutralizing efficacy at the preclinical level. 
The introduction of a new antivenom in a particular 
geographical setting should be preceded by a rigorous 
analysis of its preclinical efficacy against the venoms 
of the most relevant snakes in the region. The single 
most important test to assess neutralization of venoms 
by antivenoms is the mouse lethality test but, depending 
on the toxicological profile of the venom being tested, 
additional assays should also be included. 
Neutralization of lethality assay
 Lethality is the single most important effect to 
be tested when analysing venom toxicity and its 
neutralization by antivenoms. Thus, the gold standard 
for the assessment of preclinical antivenom efficacy is 
the neutralization of lethal activity of venoms46. First, 
the overall toxicity of venom, the median lethal dose 
(LD50), is determined, usually using the mouse model. 
To this end, serial doses of venom, diluted in saline 
solution, are injected in mice of a determined weight, 
either by the intravenous (i.v.) or the intraperitoneal 
(i.p.) routes. Deaths occurring during a predefined 
time span (24 or 48 h) are recorded and the LD50 is 
estimated by statistical methods such as Spearman-
Karber47, probits48 or non-parametric procedures. LD50 
corresponds to the venom dose which induces death 
in 50 per cent of the injected mice; it can be expressed 
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as µg venom per mouse or as µg venom per gram of 
animal weight. For the neutralization assays, a fixed 
dose of venom, known as the ‘challenge dose’, which 
corresponds to a defined number of LD50s (usually from 
3 to 6 depending on the laboratory), is selected. This 
fixed venom solution is mixed with various dilutions of 
the antivenom, in order to achieve several antivenom/
venom ratios, and the mixtures are incubated (usually 
for 30 min at 37°C). Control samples include venom 
incubated with saline solution instead of antivenom. 
Aliquots of the mixtures are then injected into mice 
and deaths are recorded. Neutralization is expressed as 
the median effective dose (ED50), i.e. the antivenom/
venom ratio in which 50 per cent of the injected mice 
survive. ED50 can be expressed in various ways, which 
varies depending on the laboratory, i.e. milligram of 
venom neutralized per millilitre antivenom, millilitre 
antivenom required to neutralize one milligram venom, 
or number of LD50s of venom neutralized per millilitre 
antivenom. The assessment of the ability of antivenoms 
to neutralize lethality is routinely performed in the 
manufacturers’ quality control laboratories and by 
national regulatory agencies, as part of regular analyses 
of the antivenoms being manufactured, purchased and 
distributed. Unfortunately, some countries rely mostly 
on data reported by the manufacturers, rather than on 
control exerted by regulatory agencies.
Towards a more complete assessment of the 
preclinical efficacy of antivenoms
 The neutralization of venom lethality is, and will 
remain, the gold standard in the preclinical testing 
of antivenom efficacy46. However, the study of the 
biochemical and toxicological complexity of snake 
venoms has shown clearly that, besides lethality, 
the venoms of many species induce additional toxic 
activities that play a key role in the pathophysiology 
of human envenoming. For example, envenomings 
by viperid snakes in many regions around the world 
are characterized by complex local tissue damage 
(myonecrosis, dermo-necrosis, haemorrhage, 
blistering) and by systemic disturbances (haemorrhage, 
coagulopathy, cardiovascular shock, acute kidney 
injury). Therefore, it has been argued that a more detailed 
analysis of the preclinical efficacy of antivenoms should 
encompass, in addition to lethality, the neutralization 
of these other clinically relevant effects46,49,50. Several 
simple in vivo and in vitro laboratory assays have 
been developed for the quantitative assessment of 
haemorrhagic, myotoxic, dermo-necrotic, coagulant, 
and defibrinogenating activities, among others51-53. 
Thus, although the routine quality control of antivenoms 
involves the neutralization of lethal activity, when a 
new antivenom is being developed, or when an existing 
antivenom is introduced to a new geographical setting, 
a comprehensive preclinical analysis of neutralizing 
efficacy should be performed against the most relevant 
toxic effects of the most important snake venoms in 
that particular region. This allows a rigorous testing 
of whether the antivenom is effective, not only 
against venom-induced lethality, but also against other 
clinically-relevant effects. A brief description of the 
fundamentals of these additional tests follows:
Haemorrhagic activity: The most widely used method 
is based on the intradermal injection of venom solutions 
followed, several hours later, by the measurement of 
the area of the haemorrhagic spot in the inner side 
of the skin. The original method was described in 
rabbits54, and has been adapted for use in rats51 and 
mice55. Venom activity is expressed as the minimum 
haemorrhagic dose (MHD), which corresponds to the 
dose of venom that induces a haemorrhagic halo of 10 
mm diameter55. More recently, the analysis of systemic 
haemorrhage has been performed by the study of 
pulmonary haemorrhage. Mice were injected i.v. with 
venom and, one hour later, the animals were sacrificed 
and the thoracic cavity exposed for observation of 
haemorrhagic spots on the surface of the lungs. The 
minimum pulmonary haemorrhagic dose (MPHD) 
corresponds to the lowest amount of venom that induces 
haemorrhagic spots in the lungs of all mice injected56. 
Myotoxic activity: Venom-induced skeletal muscle 
necrosis can be assessed by histological examination 
of muscle tissue injected with venom. Mice receive an 
intramuscular injection of venom solution, for example, 
in the gastrocnemius muscle, are sacrificed after 24 h, 
and the injected muscle dissected out, placed in fixative 
solution (e.g. formalin), and processed for histological 
analysis. The number of necrotic cells and the total 
number of muscle cells are quantified by microscopic 
assessment, and the myotoxic effect is expressed as 
the necrotic index, i.e. the ratio of necrotic muscle 
fibres to total muscle fibres57. Venom activity can be 
expressed as the dose inducing a necrotic index of 
0.5. Since histological analysis is time consuming and 
not available in many laboratories, an alternative and 
highly convenient test is based on the quantification of 
the plasma activity of the enzyme creatine kinase (CK), 
which is present in large amounts in muscle tissue and 
is released when the plasma membrane of muscle cells 
is disrupted by the action of venom myotoxins52. The 
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minimum myotoxic dose (MMD) is defined as the 
dose of venom that increases the plasma CK activity 
four times as compared to mice injected with saline 
solution58.
Dermo-necrotic activity: This effect is assessed in either 
rats or mice by carrying out intradermal injections of 
venom solutions, followed by the measurement of the 
necrotic area in the inner side of the skin 72 hour after 
venom injection51. 
Coagulant activity: In vitro coagulant activity of venoms 
is assessed by the addition of various doses of venom 
to samples of citrated human plasma, followed by the 
determination of clotting time. Activity is expressed as 
the minimum coagulant dose (MCD), defined as the 
dose of venom that induces clotting in 60 sec51,53. For 
assessing thrombin-like activity of venoms, a similar 
test is performed on fibrinogen solutions instead of 
plasma51.
Defibrinogenating activity: It is assessed in rats or 
mice by intravenous injection of venom solutions. 
After a defined period of time, a blood sample is 
collected, placed in a glass tube, and incubated at room 
temperature for observation of clot formation. Activity 
is expressed as the minimum defibrinogenating dose 
(MDD), defined as the dose of venom that induces 
incoagulability in all animals injected51,53. 
Other tests: In addition to the most frequently 
performed tests described above, other toxic activities 
can be also assessed, such as oedema-forming activity59, 
neurotoxic activity using nerve-muscle preparations ex 
vivo60, and thrombocytopenic effect61. Likewise, the 
analysis of neutralization of venom enzyme activities 
has been also investigated, such as neutralization 
of proteinase, phospholipase A2 and hyaluronidase 
activities55,62,63. As in the case of neutralization of 
lethality, a ‘challenge dose’ of venom is selected and a 
solution of a fixed dose of venom is mixed with various 
dilutions of antivenom, followed by incubation (30 
min at 37ºC). Aliquots of the mixtures are then tested 
in the corresponding assay systems described; controls 
of venom solutions incubated with saline solution 
instead of antivenom are included. Neutralization is 
expressed as ED50, i.e. the antivenom/venom ratio at 
which the effect of venom is neutralized to a 50 per 
cent64. In the case of coagulant and defibrinogenating 
activities, neutralization is expressed as effective dose 
(ED), defined as the antivenom/venom ratio at which 
the clotting time of plasma is prolonged three times 
when compared to plasma incubated with venom alone 
(for coagulant activity) or as the antivenom/venom 
ratio at which blood clots in all animals injected (for 
defibrinogenating effect)53.
Selection of tests for preclinical evaluation of 
antivenoms should be based on the toxicological 
profile of venoms
 Since snake venoms are highly variable in their 
toxicological profiles, the selection of laboratory tests 
to be implemented for the preclinical evaluation of 
antivenom efficacy should be based on the toxicological 
profile of venoms and on the predominant clinical 
manifestations of envenomings. The following are 
some examples:
(i) Venoms of elapid snakes exerting predominantly 
neurotoxic effect: The venoms of a large variety 
of elapid snakes exert, both at the clinical and the 
experimental levels, a predominant neurotoxic effect, 
based on the action of either presynaptically-acting 
phospholipase A2 (PLA2s), such as β-bungarotoxin 
from species of Bungarus, or post-synaptically-acting 
neurotoxins of the ‘three finger family’, known as 
α-neurotoxins, which bind with strong affinity to 
the nicotinic cholinergic receptor at the motor end-
plate. These neurotoxins act at the peripheral nervous 
system and generate flaccid paralysis which, when 
affects respiratory muscles, might result in respiratory 
paralysis and death65. The preclinical efficacy of 
antivenoms against these venoms can be assessed by 
the neutralization of lethal effect (the ED50 test), since 
the end result of neurotoxicity is death. Thus, in the 
cases of venoms of many species of cobras (Naja sp.) 
and kraits (Bungarus sp.), neutralization of lethality 
suffices to test the preclinical efficacy of antivenoms45.
(ii) Venoms of viperid snakes: Despite presenting 
significant variations in venom composition and 
activities between and within species, viperid venoms 
are generally characterized for inducing local tissue 
damage (i.e. haemorrhage, myonecrosis and oedema) 
and systemic alterations associated with haemorrhage, 
coagulopathy, cardiovascular disturbances and renal 
damage65. Therefore, the preclinical assessment of 
antivenoms against viperid venoms should include the 
analysis of lethal, haemorrhagic, myotoxic, coagulant, 
and defibrinogenating activities of venoms66. This 
would be the case of the venoms of Echis sp., Daboia 
sp. and Hypnale sp. in the Indian subcontinent. 
(iii) Other venoms: Venoms of a number of spitting 
cobras in Africa and Asia induce predominantly a 
local necrotising effect in humans65,67. In these cases, 
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antivenoms should be assessed for their capacity to 
neutralize lethality and dermo-necrosis68. Sea snake 
venoms induce, in addition to neurotoxic effect, 
a systemic myotoxic action which might result in 
rhabdomyolysis. Hence, antivenoms should be tested 
for the neutralization of lethal and myotoxic activities66. 
On the other hand, the venoms of some Australian 
land elapids induce neurotoxicity, myotoxicity and 
coagulopathy; consequently, preclinical evaluation of 
antivenoms should include the neutralization of these 
effects69.
 When an antivenom, which is being developed or 
introduced to a new geographical setting for the first 
time, is shown to be effective at the preclinical level, 
subsequent routine quality control of its efficacy can be 
based on the neutralization of lethality only. 
The issue of venom variability and the preparation 
of venom pools
 A key aspect in the preclinical assessment of 
antivenom efficacy is the quality and representativeness 
of the venoms used to test neutralization. There may be 
a large intraspecific variability in venom composition, 
especially in species of wide geographical distribution, 
such as Daboia russelii in Asia43, Bitis arietans in 
sub-Saharan Africa70 and Bothrops atrox in South 
America71. In these and in similar cases, it is necessary 
to ensure that the venoms utilized correspond to 
representative pools prepared from specimens 
distributed in different geographical locations40,46. 
These venom pools should be prepared from specimens 
acquired from right across the range of the species, that 
have been correctly identified, since the traceability 
of the venoms for preclinical testing is of paramount 
relevance. Ideally, each country should have snake 
collections and laboratories for maintenance of snakes 
and for venom collection and storage, following 
appropriate standardised protocols46 and, the preclinical 
assessment of antivenom efficacy should be carried out 
with venoms from specimens collected in the region 
where this antivenom is intended to be used. This task 
demands national and international cooperation from 
health authorities, National Regulatory Agencies, 
independent scientists and manufacturers to ensure the 
qualification of snake collections and venom sources 
and the adequacy of selected preclinical tests for the 
species venoms concerned. Furthermore, protocols for 
quality control of venoms used in antivenom production 
and evaluation should be also implemented according 
to the national and international standards46.
The need for the development of in vitro tests for 
assessing antivenom preclinical efficacy
 Many of the tests used for the preclinical evaluation 
of antivenoms involve the use of experimental animals, 
mostly mice. Since venoms induce pain and other effects 
in these animals, there is a growing concern about this 
issue and interest in finding suitable surrogate in vitro 
tests that could be used in the evaluation of antivenoms. 
One of the main drawbacks for achieving this goal has 
to do with the great biochemical and toxicological 
complexity of venoms, in which several relevant effects 
are induced by different venom components66. Despite 
this limitation, some advances have been achieved, 
such as determining procoagulant activity in vitro40, and 
using enzyme immunoassays whose results correlate 
with the neutralization of lethality72-74. However, 
compared to the murine ED50 assay, the neuromuscular 
preparation assay requires a high degree of skill and 
experience to perform it well, and the technique is not 
easily reproducible from one laboratory to another. In 
addition, the use of chicken embryos at a stage prior to 
the development of pain sensitivity has been proposed 
as an alternative to rodent tests for assessing lethal 
and haemorrhagic activities of viperid venoms75. The 
search for alternative in vitro tests for assessing the 
neutralizing ability of antivenoms is an area of research 
and development that deserves urgent attention. In 
particular, at the start of the 21st century, developments 
in proteomics-centred approaches for assessing the 
detailed composition of venoms (venomics) and the 
immunochemical profile of antivenoms (antivenomics) 
are likely to revolutionise the design and pre-clinical 
assessment of antivenoms, especially in predicting 
paraspecific neutralization. The operational principles 
of these approaches are discussed below.
International cooperative projects should be 
implemented to assess the preclinical efficacy of 
antivenoms on a worldwide basis
 The analysis of the neutralizing ability of 
antivenoms at the preclinical level has been the focus 
of a number of collaborative research projects in Latin 
America. As a consequence, a large body of evidence 
has accumulated and, on this basis, the public health 
authorities in the region are able to make informed 
decisions on antivenom acquisition and deployment in 
several countries. Examples are studies performed in 
Argentina76, Brasil77,78, Perú58, Colombia79, Ecuador80, 
Costa Rica55,77 and Guatemala81. Recently, a large 
collaborative regional project evaluated several 
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antivenoms against the venoms of the medically most 
important Bothrops species in the region82. In contrast, 
studies on the preclinical efficacy of antivenoms in 
Africa and Asia have been scarce and there is a large 
gap in our knowledge of the cross-neutralization of 
viperid and elapid snake venoms by antivenoms used 
in these continents. For instance, several antivenoms 
are distributed in sub-Saharan Africa, but only a 
few studies have reported data on their preclinical 
neutralizing profile83-86; moreover, venoms from 
snakes of many African countries have not been tested 
for their neutralization by antivenoms. This situation 
jeopardises efforts to bring antivenoms to large areas 
of Africa and Asia since the introduction of antivenoms 
for clinical use without preclinical information on their 
efficacy, is not recommended.
 The solution to this problem demands concerted 
international efforts involving diverse partners, 
including herpetologists, toxinologists, antivenom 
manufacturers, epidemiologists and public health 
authorities, among others. The development and 
strengthening of local groups, in universities and 
ministries of health in developing countries, in the 
preclinical testing of antivenoms are of paramount 
importance and should be promoted through national 
and international workshops and training programmes. 
Likewise, the establishment of snake collection facilities 
and laboratories responsible for obtaining venoms are 
required to ensure the proper identification and quality 
assurance of venoms to be used in preclinical testing. 
Research laboratories working on venom proteomics 
and other classical and “omics” aspects of toxinology 
are essential to generate detailed knowledge of venom 
composition and variability. 
 The Global Snakebite Initiative (GSI, http://
www.snakebiteinitiative.org), with the support of the 
International Society on Toxinology (IST, http://www.
toxinology.org), has proposed an international strategy 
to improve our knowledge of the composition of the 
medically most important venoms, as well as of the 
ability of currently available antivenoms to neutralize 
these venoms at the preclinical level7. This knowledge 
may pave the way for the design of novel, knowledge-
based immunizing mixtures with the aim of generating 
polyspecific antivenoms of broad efficacy, particularly 
in sub-Saharan Africa and Asia. Already, GSI has 
developed protocols for Indian researchers to enable 
them to collect very high quality venom samples in 
the field, and return these to the laboratory for analysis 
without degradation. Efforts are now focusing on 
ensuring that these venoms are used in well-designed, 
relevant assays to measure preclinical effectiveness of 
current Indian antivenoms. A pilot study, examining 
venom variation in Russell’s vipers from different 
locations in India, and the ability of commercial 
antivenoms to neutralize all of the venoms has been 
designed and local researchers have begun collecting 
the venom samples (personal communication of 
Chellam R, Martin G, Whitaker R, et al, Madras 
Crocodile Bank Trust).
Proteomic tools for exploring the venom proteome
Snake venomics: Research on venoms has been 
continuously enhanced by advances in technology. 
Advances in instrumentation and high-throughput 
“omics” methodologies have fuelled an expansion 
of the scope of biological studies from simple 
biochemical analyses involving a few molecules 
at a time to the systematic study of whole genomes, 
transcriptomes, and proteomes. Specifically, the last 
decade has witnessed the development of techniques 
and strategies for assessing the toxin composition 
of snake venoms (“venomics”), directly (through 
proteomics-centred approaches)8,87,88 or indirectly 
(via high-throughput venom gland transcriptomics 
and bioinformatic analysis)89-91 in a relatively rapid 
and cost-effective manner. Bottom-up proteomics 
remains the workhorse for venomic analysis. Standard 
approaches include the tryptic digestion of the proteins 
into peptides, previously separated through single- or 
multi-dimensional protocols combining electrophoretic 
and chromatographic techniques87,88. These are then 
sequentially isolated in the mass spectrometer and 
sequenced by analysis of their fragmentation pattern. 
Parent proteins can then be identified by database 
searching strategies92. Proteomics-centred venomics 
requires homologous searchable databases for 
exploiting fully its analytical capabilities93-96. However, 
the slow progress in the generation of genomic and 
transcriptomic databases precludes the application of 
automated high-throughput proteomic approaches to 
study venoms. In addition, in the absence of reliable 
automatic de novo sequencing mass spectrometric 
algorithms, snake venom proteome investigation 
remains a laborious task. Recent contributions to the 
literature of venom proteomics emphasised that sample 
de-complexation before mass spectrometry represented 
the best approach for maximizing proteome coverage97. 
Fractionation via multi-dimensional techniques and 
strategies for the depletion of high abundance proteins, 
as well as the enrichment of extremely low abundance 
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proteins to mine the venom proteome more effectively, 
have been investigated98,99. Clearly, if sufficient pre-
mass spectrometric and mass spectrometric efforts are 
applied, thorough proteomic coverage can be achieved 
by an experienced researcher. 
 Our snake venomics approach7-9,100 (Fig. 7) 
includes an initial step of fractiona tion of the crude 
venom by reverse-phase (RP) HPLC followed by the 
initial characterization of each protein fraction by a 
combination of N-terminal sequencing, SDS-PAGE, 
and mass spectrometric determina tion of the molecular 
masses, and eventually the cysteine (-SH and S-S) 
content, of the isolated components. RP-HPLC allows 
the quantitative recov ery of all venom components 
present in the molecular mass range of 7–150 kDa that 
can be separated by conventional 2DE. Further, the 
initial part of the acetonitrile gradient of the reverse-
phase chromatography resolves peptides and small 
pro teins (0.4–7 kDa), which would not be recovered 
from a 2DE separation. Monitoring the eluate at the 
absorption wavelength of the peptide bond (190-230 
nm) represents a reliable method for quantifying the 
relative abundance of the different venom components 
in the reverse-phase chromatogram8,9. In-gel digestion, 
peptide mass fingerprinting, and de novo peptide 
sequencing by collision-induced dissociation (CID)-
tandem mass spectrometry (MS/MS) coupled to database 
search by BLAST analysis allow the unambiguous 
assignment to known or unknown protein families of 
all venom toxin bands visualized in a Coomassie blue-
stained SDS-polyacrylamide gel. Sequence coverage 
becomes an important issue to differentiate between 
the different classes of multi-domain proteins, such as 
the haemorrhagic Zn2+-dependent metalloproteinases 
(SVMP), whose pharmacological activities are 
modulated by their distinct domain structures101.
 Venomics analyses involving nearly 100 taxa 
have revealed that snake venoms are mixtures of 
pharmacologically active proteins and peptides 
synthesized from several tens to a few hundred of unique 
gene products89-91, which, however, belong to only a 
handful (<13) of toxin families8-10,87,88. A major goal of 
bottom-up venomics is to measure the full chemical 
space within which the pathological effects of snakebite 
envenoming are manifested. Another prime challenge 
of venomics is the formulation of rigorous biological 
hypotheses based on the information gathered by the 
discovery-based proteomics platform. In this respect, it 
is worth recalling the words of the prominent geneticist 
and evolutionary biologist, Theodosius G. Dobzhansky: 
“Nothing in biology makes sense except in the light of 
evolution”102. Understanding the molecular mechanisms 
and evolutionary trends that underlie inter- and 
intra-specific venom variation provides insights into 
snakebite pathology103-110. The occurrence of variability 
in the biochemical composition of venoms and in the 
symptomatology after envenomation by snakes from 
different geographical locations and age has long been 
appreciated by herpetologists and toxinologists38,111, 
although detailed comparative analyses were scarce 
in the literature before 2008. A specific question 
that we have assessed in recent years by venomics 
includes the occurrence and onset of geographical and 
ontogenetic variations in Bothrops asper107, B. atrox71, 
the Crotalus durissus complex105,112, C. tigris113, C. 
scutulatus106, Sistrurus miliarius barbouri114, and 
across genus Lachesis115. Emerging views of these, and 
other continuing studies indicate that (i) geographical 
variability is a general phenomenon and phenotypic 
variation across the population encompasses two 
distinct but overlapping causal factors: individual and 
ontogenetic variations. The occurrence of intraspecific 
individual allopatric variability highlights the concept 
that a species should be considered as a group of meta-
populations; (ii) ontogenetic changes follow genus-
specific trends71,107,112-115; and (iii) within a species range, 
paedomorphic and ontogenetic venom phenotypes often 
occur in geographically differentiated areas71,107,116,117. 
Translational venomics: antivenomics
 A robust knowledge of the toxin composition of 
venoms and the recognition of convergent and divergent 
trends along venom evolution is of fundamental 
importance in the selection of species and specimens for 
the manufacture of improved therapeutic antivenoms. 
This is particularly relevant for highly adaptable and 
widely distributed species, in which allopatric venom 
variability represents a source of diversity of the 
pathological effects of envenoming. To help antivenom 
design and to assess the range of possible clinical 
application of currently commercial or experimental 
mono- and polyspecific antivenoms, we have developed, 
since 2008, “antivenomics”118. Antivenomics is a 
proteomics-based protocol to quantify the extent of 
cross-reactivity of antivenoms against homologous 
and heterologous venoms110,119,120. First generation 
antivenomics consisted of the immuno-depletion of 
toxins upon incubation of whole venom with antivenom 
followed by the addition of a secondary antibody. 
Antigen-antibody complexes immuno-depleted from 
the reaction mixture contain the toxins against which 
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Fig. 7. Venomics workflow. The bottom-up venomics approach includes an initial step of fractiona tion of the crude venom by reverse-phase 
(RP) HPLC (1) followed by the initial characterisation of each protein fraction by means of N-terminal sequencing (2), mass determination by 
MALDI- or ESI-MS (3), and SDS-PAGE (4). Tryptic peptides generated by in-gel digestion of electrophoretic bands are subjected to peptide 
mass fingerprinting (5), and de novo peptide sequencing by collision-induced dissociation (CID)-tandem mass spectrometry (MS/MS) (6). 
MS/MS-derived amino acid sequences are assigned to toxins/toxin families by database searching (7) and BLAST analysis (8). Structural 
assignments and the relative abundance of the venom’s toxin families are integrated into a pie chart (9). Pie charts offer a simple way of 
displaying the toxin profile of a venom and represent an intuitive method for comparing quantitative data across different taxa.
antibodies in the antivenom are directed. By contrast, 
venom components that remain in the supernatant are 
those which failed to raise antibodies in the antivenom, 
or which triggered the production of low-affinity 
antibodies. These components can be easily identified 
by comparison of reverse-phase HPLC separation of 
the non-precipitated fraction with the HPLC pattern 
of the whole venom previously characterized by 
venomics. Second generation antivenomics119 is an 
affinity chromatography protocol to investigate the 
immuno-capturing ability of immobilized F(ab′)2120,121 
or IgG123antibody molecules followed by the proteomic 
characterization of the bound and the non-bound 
venom components (Fig. 8). Antivenomics provides 
qualitative and quantitative information on both the set 
of toxins bearing antivenom-recognized epitopes and 
those toxins exhibiting poor immunoreactivity. Its ease 
of use, reproducibility, sensitivity, and low cost suggest 
the possibility that antivenomics might supplant the use 
of immunoassays and Western blots, the most popular 
techniques for assessing the immunoreactivity of 
antibodies. However, the immuno-chemical detection 
of blotted proteins provides a Yes/No response: a given 
protein is either recognized or not by the antivenom, 
and it is essentially a non-quantitative technique. 
 Despite its recent introduction, the usefulness and 
validity of antivenomics to complement the in vivo 
standard preclinical assays of neutralization of lethality 
and toxic activities by antivenoms has been extensively 
demonstrated68,105,120-123. Antivenomics thus provides a 
ground for rationalizing the paraspecificity of antivenoms 
thereby expanding their potential clinical range. 
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Current venomics analyses of Indian snakes of 
medical relevance
 The common krait (Bungarus caeruleus) (Fig. 
1a), the Indian cobra (Naja naja) (Fig. 2a), Russell’s 
viper (Daboia russelii) (Fig. 3a), and the saw-scaled 
viper (Echis carinatus) (Fig. 4a), collectively called 
the “Big 4”, are considered to be the major endemic 
venomous snakes responsible for fatality in the Indian 
subcontinent124. The efficient clinical management 
of snakebites requires timely administration of 
appropriate antivenoms that neutralize the numerous 
toxins contained in the snake venom. Antivenoms 
against the “big four”, produced by several Indian firms 
(http://apps.who.int/bloodproducts/snakeantivenoms/
database/default.htm) are available. However, detailed 
studies on the immunoreactive properties of these 
polyvalent antivenoms have not been performed. To 
complicate matters, the emergence of the hump-nosed 
pit viper (Hypnale hypnale) (Fig. 5a) and other species 
as snakes of medical significance in south-western 
India36,124 , has rendered the “Big 4” obsolete and 
incomplete. 
 Snake venomics of the eastern Russell’s viper 
(Daboia siamensis) and its relation to pharmacological 
activities have been addressed by Risch and 
coworkers125. D. siamensis is found in Burma, Thailand, 
Cambodia, parts of China, Taiwan and Indonesia126,127. 
The clinical manifestations of Russell’s viper bite 
Fig. 8. Antivenomics workflow. Left panel, whole venome (V) is applied to an immunoaffinity column (1) packed with antivenom antibodies 
immobilized onto Sepharose beads (2). After eluting the non-binding fraction (3), the column is thoroughly washed with equilibration 
buffer (4) and the immunocaptured proteins eluted (6) with elution buffer (5). Right display, panels A-C show, respectively, reverse-phase 
chromatographic separations of the components of whole venom, the fraction retained and subsequently recovered from the antivenom affinity 
matrix, and the non-immunocaptured venom fraction. Proteins within the immunocaptured and the flow-through fractions are identified by 
the venomics approach schematically displayed in Fig.7.
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vary from one region to another within Southeast 
Asia, including India43,128-130. Some studies on the 
biochemical properties of Russell’s viper venom from 
eastern India that correlate with the distinct clinico-
pathological manifestation in Russell’s viper bites have 
been reported130. In particular, non-enzymatic peptides 
present in Daboia russelii (Eastern region) venom, 
and which render commercial polyvalent antivenom 
ineffective, have been detected41. The identity of 
these venom components has not been determined. 
In addition, there is a dearth of knowledge about the 
qualitative and quantitative protein composition of D. 
russelii venom across the Indian peninsula. 
 The Indian cobra, Naja naja, and the common 
krait, Bungarus caeruleus (Elapidae) cause severe 
neuromuscular paralysis as a result of the blockade 
of neuromuscular transmission. Toxins from cobra 
venom predominantly act postsynaptically, whereas 
those from krait venom mainly act presynaptically131. 
The common krait is regarded as the most dangerous 
species of venomous snake in the Indian subcontinent. 
Chemical and pharmacological characterization of toxic 
polypeptides from the venom of B. caeruleus have been 
long reported131,132. The major neurotoxic component 
of krait venom is β-bungarotoxin, a heterodimeric 
basic PLA2 which has high affinity for presynaptic 
neuromuscular receptors133. However, a global picture 
of the toxin composition and geographical variability 
of B. caeruleus venom is lacking. Similarly, although 
there are 32 UniProtKB/TrEMBL entries of Indian cobra 
venom toxins, the relative contribution of these proteins 
to the whole venom remains undisclosed. Furthermore, 
regional variation in venom composition and toxicity 
has also been described for Indian N. naja134,135: eastern 
N. naja venom is neurotoxic (being PLA2 molecules 
largely responsible for the toxicity) and procoagulant (in 
vitro, not clinically), whereas western region venom is 
myotoxic and anticoagulant (in vitro, not clinically)132. 
Region-specific neutralization of Indian cobra (Naja 
naja) venom by polyclonal antibody raised against 
the eastern venom has been published42. However, the 
identity of the geographically variable molecules and 
the immunoreactivity pattern of available antivenoms 
towards regional venoms deserve future studies. 
 A large proportion of the 71 E. carinatus venom 
protein sequences available in the UniProtKB/TrEMBL 
database (http://www.expasy.org) has been derived 
by venom gland transcriptome surveys using cDNA 
libraries constructed from ten wild-caught specimens of 
E. carinatus sochureki from Sharjah, UAE136,137. Their 
expression and relative abundance in the venom have 
not been addressed. The phylogeny of the medically 
important, and taxonomically unresolved, viper genus 
Echis has been investigated by Pook and colleagues138. 
The results showed that the populations of the genus 
fall into four main clades: the Echis carinatus, E. 
coloratus, E. ocellatus and E. pyramidum groups. 
The E. carinatus group includes haplotypes from 
India (E. c. carinatus), Pakistan and the northeastern 
Arabian Peninsula (E. c. sochureki) that form a cluster 
without clear phylogeographical structure. More basal 
sister haplotypes originate from western and southern 
India. Whether E. c. sochureki should be recognised 
as distinct from southern Indian E. c. carinatus at 
species or subspecies level remains an open question. 
Although the low divergence between northwestern 
Indian, Pakistani, northeastern Arabian and Central 
Asian E. carinatus populations indicated that these 
haplotypes first diverged approximately 0.9 Mya138, the 
link between the transcriptomic data gathered from the 
E. c. sochureki specimens from Sharjah, UAE and the 
venom proteome composition of the Indian populations 
of E. c. carinatus (South Indian saw-scaled viper; 
peninsular India) remains obscure. 
 Snakes of the genus Hypnale are of local medical 
importance in Sri Lanka and southwestern India 
and pathological effects of the venom of Sri Lankan 
Hypnale in animals was the subject of some early 
studies139. Recently, Maduwage and colleagues140 have 
investigated the biochemical and pharmacological 
properties of the venoms from the three Hypnale 
species in Sri Lanka. Cytotoxicity appeared to be the 
most potent effect of these venoms, which had similar 
reverse-phase chromatographic toxin profiles. Indian 
polyvalent antivenom raised against Naja naja, Daboia 
russellii, Bungarus caeruleus and Echis carinatus did 
not neutralize the venom effects140. Kumar and Sabitha141 
have also reported that available Indian anti-snake 
venom in central Kerala does not cover envenomation 
by H. hypnale. Cross-neutralization in vitro and in a 
rodent model of H. hypnale venom by polyvalent and 
monovalent antivenoms against Malayan pit viper 
(Calloselasma rhodostoma) venom, a sister taxon of 
H. hypnale142, has been documented143. Establishing 
the molecular basis for this finding requires detailed 
venomics and antivenomics investigation. 
Remarks and perspectives
 An essential defining characteristic for a biological 
hypothesis is its ability to generate testable predictions. 
Developments in venomics and antivenomics are likely 
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to revolutionize the design and preclinical assessment 
of antivenoms by bringing to bear technologies that 
enable us to peel back the layers of imprecision that 
exist in current methodologies, and get to heart of the 
problem by being able to design and test new antivenom 
preparations developed using these dynamic platforms. 
Antivenomics represents a knowledge-based approach 
to help to design improved venom-based immunogen 
mixtures, and to predict paraspecific neutralization 
by antivenom preparations to the level of species-
specific toxins. In India, antivenom production began 
at the Central Research Institute, Kasauli during the 
1920s. There are now several producers manufacturing 
Indian polyvalent antivenoms, all of which follow 
a standard set out in the Indian Pharmacopoeia 
requiring products to neutralize 0.6 mg/ml Naja naja 
venom, 0.6 mg/ml Daboia russelii venom, 0.45 mg/
ml Bungarus caeruleus venom and 0.45 mg/ml Echis 
carinatus venom. This potency is much lower than the 
standards that applied during the early 1950s when 
Indian antivenoms were required to neutralize 4.0 mg/
ml Daboia russelii venom and 2.0 mg/ml Naja naja 
venom144. This low potency demands that patients be 
given initial doses of at least 10 vials. In some cases, 
considerably larger doses are administered. A study in 
Chandigarh found that patients received an average of 
51.2 vials (512 ml) of Indian polyvalent antivenom for 
bites by Naja sp., and Bungarus sp., and an average 
of 32 vials (320 ml) to treat Daboia russelii or Echis 
carinatus envenoming. At the extreme, some patients 
received as many as 130 vials (1.3 litres) for bites by 
Russell’s vipers; while up to 190 vials (1.9 litres) were 
administered after a neurotoxic snakebite145. Such high 
doses of immunoglobulin carry the risk of inducing 
severe dose-related adverse reactions, including 
anaphylaxis146-148. Clearly, new strategies are needed 
to meet the challenge of neutralizing large injected 
doses of venom without compromising patient safety. 
Production of higher potency antivenoms will be 
required. Some of the snake species that occur in India 
produce large amounts of venom; Asian cobras (Naja 
sp.) have yields ranging from 58-742 mg149, kraits 
can produce 8-60 mg150 and Russell’s vipers venom 
yields a range from 21-268 mg151. A new antivenom, 
recently produced in Costa Rica for the treatment of 
Papuan taipan (Oxyuranus scutellatus) envenoming 
in Papua New Guinea, has addressed the problem of 
balancing antivenom potency and dose against the 
average venom yield (120 mg) of the species involved. 
A single 40 ml vial of antivenom, with a potency 
standard of at least 3 mg/ml and total protein of just 
4.59±0.9 g/dl, should allow an initial treatment dose 
of 1 vial to neutralize at least 120 mg O. scutellatus 
venom69. Modern proteomic and antivenomic methods 
have been employed in the characterization of this 
venom and in the preclinical evaluation of this new 
antivenom. Such an approach could easily be used 
to design and produce a high potency polyvalent 
antivenom for use in India. The new antivenom could 
be evaluated preclinically and then subjected to clinical 
trial. This evidence might persuade Indian regulators to 
adopt new specifications for antivenom in the Indian 
Pharmacopoeia.
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